10-Q quarterly report · filed Nov 4, 2026

Nuvectis Pharma, Inc. (NVCT) Q3 2026 10-Q Quarterly Report

Short answer

Nuvectis Pharma, Inc. (NVCT) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$30M
−303.0% YoY · −328.3% QoQ
EPS (diluted)
−$1.13
−151.1% YoY · −276.7% QoQ

Source: XBRL data from the Nuvectis Pharma, Inc. (NVCT) Q3 2026 10-Q on SEC EDGAR. USD.

Nuvectis Pharma, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product revenue since inception
  • Net loss $30.1M vs $7.5M YoY, operating loss $31.0M vs $7.8M
  • Worst performer: NXP100, NXP200 and NXP900 development drove R&D $27.4M vs $5.8M
  • Cash $140.7M, operating cash use $36.3M, financing cash inflow $145.4M
  • Outlook: cash expected to fund operations through at least 12 months, additional capital required long term

Risk Factors

  • New risk: U.S. trade-policy changes affecting China-originated NXP100 and NXP200 materials, technology, and clinical data
  • New risk: Tariffs could increase research costs, although no tariffs affected operations as of September 30, 2026
  • Regulatory risk: One Big Beautiful Bill Act FDA workforce reductions could delay product approvals
  • Operational risk: Dependence on Haisco for NXP100 and NXP200 technology transfer and material supply
  • Financial risk: Accumulated deficit reached $142.8 million through September 30, 2026, requiring substantial additional funding

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Nuvectis Pharma, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.